GSK (FKA GLAXOSMITHKLINE INC.) for GSK (FKA GLAXOSMITHKLINE INC.)
What was lobbied
7 issue areas, each in the filer's own words, with who lobbied on it and where.
Tariff (miscellaneous tariff bills) TAR
None
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOSEPH MCGOWAN | — |
Trade (domestic/foreign) TRD
H.R. 1314 Trade Act of 2015 Provisions related to Trade Promotion Authority No bill # assignedTrans-Pacific Strategic Economic Partnership Agreement (TPP)provisions related to intellectual property, market access and public health issues No bill # assignedTransatlantic Trade and Investment Partnership (TTIP)provisions related to market access intellectual property, regulatory harmonization and other issues No bill # assignedInternational market access and intellectual property issues No bill # assignedCanada IP and market access issues
| Lobbyist | Covered position, as disclosed |
|---|---|
| SHIRA KILCOYNE | — |
| JOSEPH MCGOWAN | — |
| WILLIAM J SCHUYLER | — |
| KIMBERLY A WILLIAMS | — |
Taxation/Internal Revenue Code TAX
H.R. 880American Research and Competitiveness Act of 2015A bill to modify and make permanent the research and development (R&D) tax credit
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOSEPH MCGOWAN | — |
| WILLIAM J SCHUYLER | — |
| JULIE VENNERS CHRISTENSEN | — |
| KIMBERLY A WILLIAMS | — |
Copyright/Patent/Trademark CPT
S. 131: Fair And Immediate Release of Generic Drugs Act (FAIR Generics Act) - Provisions related to patent settlements and patent enforcement S. 214 - Preserve Access to Affordable Generics Act (113th Congress) - Provisions related to patent settlements S. 481: Improving Regulatory Transparency for New Medical Therapies Act - Provisions related to patent term restoration S. 632: STRONG Patents Act of 2015 - Provisions related to post-grant proceedings, bad faith demand letters, and PTO diversion S. 1137: PATENT Act - Provisions related to patent litigation reform and post-grant proceedings at the Patent and Trademark Office (PTO) S. 1421: Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2015 - Provisions related to exclusivity S. 2019: Preserve Access to Affordable Generics Act - Provisions related to patent settlements S. 2023: Prescription Drug Affordability Act of 2015 - Provisions related to patent settlements S. 2030: Advancing Targeted Therapies for Rare Diseases Act of 2015 - Provisions related to leveraging of data S. 2041: Promoting Life-Saving New Therapies for Neonates Act of 2015 - Provisions related to exclusivity H.R. 9: Innovation Act - Provisions related to patent litigation and post-grant proceedings at the PTO H.R. 406: Combination Drug Development Incentive Act of 2015 - Provisions related to exclusivity and clinical investigations essential to approval H.R. 639: Improving Regulatory Transparency for New Medical Therapies Act - Provisions related to patent term restoration H.R. 971: Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2015 - Provisions related to extension of marketing exclusivity H.R. 1353: PATIENT Act of 2015 - Provisions related to extension of marketing exclusivity H.R. 2045: Targeting Rogue and Opaque Letters Act of 2015 - Provisions related to demand letters Issues related to abuse deterrent exclusivity incentives Patent litigation reform issues and issues related to post-grant proceedings at the PTO Patent settlement policy issues Biopharmaceutical innovation and patent policy issues
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOSEPH MCGOWAN | — |
| WILLIAM J SCHUYLER | — |
| JULIE VENNERS CHRISTENSEN | — |
| KIMBERLY A WILLIAMS | — |
Health Issues HCR
H.R. 2629 Antibiotic Development to Advance Patient Treatment Act Provisions related to the approval of certain drugs for use in a limited population of patients H.R. 1537H.R. 1537: Advancing Hope Act of 2015 Provisions related to making permanent pediatric rare disease voucher program H.R. 909(CURE) Act Provisions related to expanded access H.R. 880 American Research and Competitiveness At of 2015 Provisions to make permanent the research and development (R&D) tax credit H.R. 786 Vaccine Access, Certainty, and Innovation Act of 2015 Provisions related to vaccine development H.R. 6 21st Century Cures Act Provisions related to biopharmaceutical discovery, development, delivery and transparency S. 1128 Preserving Access to Orphan Drugs Act Provisions related to orphan drug tax (113th Congress) H.R. 1547 Family Health Care Flexibility ActProvisions relating to reimbursement of OTC drugs under flexible spending and health savings accounts No bill # assigned Antibiotic Development to Advance Patient Treatment ActProvisions related to antibiotics and drug approvalAllHouse/Senate S. 836Family Health Care Flexibility Actprovisions relating to reimbursement of OTC drugs under flexible spending and health savings accounts S. 122Safe and Affordable Drugs from Canada Actprovisions related to drug importation S. 185PATH Act provisions related to antibiotics and drug approval S. 320Medical Innovation Act of 2015provisions related to NIH funding and covered manufacturer supplemental fees No bill # assignedImplementation issues relating to the Patient Protection and Affordable Care Act (PPACA) (Public Law 111-148), including Standards Related to Essential Health Benefits, Actuarial Value, and Accreditation rulemaking No bill # assigned21st Century Cures Initiative and related policy issues No bill # assignedFDA special medical useissues related to limited population antibacterial drug approval pathway No bill # assignedFDA accelerated approval policy issues No bill # assignedComparative effectiveness policy issues No bill # assignedBiopharmaceutical innovation policy issues No bill # assignedPharmaceutical supply chain security issues No bill # assigned340B policy issue No bill # assignedImplementation issues relating to the Physician Payment Sunshine Act No bill # assignedSupport for COPD national action plan No bill # assignedFDA proposed rule regarding generic drug labeling under the 1984 Hatch-Waxman amendments to the FDCA No bill # assignedFDA proposed rule regarding electronic distribution of Content of Labeling for Human Prescription Drug and Biological product HR. 3299 - the Strengthening Public Health Emergency Response Act of 20
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOSEPH MCGOWAN | — |
| WILLIAM J SCHUYLER | — |
| JULIE VENNERS CHRISTENSEN | — |
| KIMBERLY A WILLIAMS | — |
Medicare/Medicaid MMM
H.R. 2581 Preservation of Access for Seniors in Medicare Advantage Act of 2015 Provisions related to changes to the Medicare Advantage Program H.R. 2570 Strengthening Medicare Advantage through Innovation and Transparency for Seniors of 2015Provisions related to changes to the Medicare Advantage Program H.R. 1190 H.R. 1190: Protecting Seniors Access to Medicare Act of 2015 Provisions related to IPAB repeal S. 1369Value-Based Insurance Design Seniors Copayment Reduction Act of 2015 Provisions related to changes to the Medicare Advantage Program S. 1083 Medicare Drug Savings Act of 2015 S. 141 Protecting Seniors' Access to Medicare Act of 2015 Provisions related to Independent Payment Advisory Board (IPAB) repeal S. 31 Medicare Prescription Drug Price Negotiation Act of 2015 Provisions related to Secretary negotiation authority in Part D program H.R. 1190 Protecting Seniors' Access to Medicare Act of 2013provisions related to the Independent Payment Advisory Board H.R. 1470 SGR Repeal and Medicare Provider Payment Modernization Act of 2015Provisions related to SGR reform H.R. 4187 Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) S. 31Medicare Prescription Drug Price Negotiation Act of 2013provisions related to Part D issues S. 141Protecting Seniors' Access to Medicare Act of 2013provisions related to the Independent Payment Advisory Board S. 648Medicare Formulary Improvement Actprovisions related to Medicare Part D No bill # assignedProposals to increase co-payments for Part D beneficiaries receiving the low-income subsidy No bill # assignedIssues related to better use of medicines and comprehensive medication management No bill # assignedVaccine access and coverage issues HR. 512 - the Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2014 S. 2055 - the Medical Countermeasure Innovation Act of 2015
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOSEPH MCGOWAN | — |
| WILLIAM J SCHUYLER | — |
| JULIE VENNERS CHRISTENSEN | — |
| KIMBERLY A WILLIAMS | — |
Budget/Appropriations BUD
Sen. Con. Res 11 amendments relevant to the biopharmaceutical industry including Medicare Part D H. Con. Res. 27 amendments relevant to the biopharmaceutical industry including Medicare Part D H.R 1078 Food and Drug Administration Safety Over Sequestration Act of 2015 - Provisions related to exemption of certain user fees from sequestrationProvisions related to drug reimbursement, Part D, and biopharmaceutical research No bill # assigned2016 Agriculture Appropriations Bill Provisions related to compounding and e-labeling No bill # assignedThe Presidents FY 2016 Budget Provisions related to prescription drug reimbursement and data exclusivity. No bill # assignedFY 2016 Budget Resolution/Budget Control ActProvisions related to spending caps No bill # assignedBudget Control Act Provisions related to drug reimbursement, Part D, and biopharmaceutical research
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOSEPH MCGOWAN | — |
| WILLIAM J SCHUYLER | — |
| JULIE VENNERS CHRISTENSEN | — |
| KIMBERLY A WILLIAMS | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.